532 related articles for article (PubMed ID: 25322871)
1. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
Su JC; Chiang HC; Tseng PH; Tai WT; Hsu CY; Li YS; Huang JW; Ko CH; Lin MW; Chu PY; Liu CY; Chen KF; Shiau CW
Carcinogenesis; 2014 Dec; 35(12):2807-14. PubMed ID: 25322871
[TBL] [Abstract][Full Text] [Related]
2. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
Su JC; Tseng PH; Wu SH; Hsu CY; Tai WT; Li YS; Chen IT; Liu CY; Chen KF; Shiau CW
Neoplasia; 2014 Jul; 16(7):595-605. PubMed ID: 25047655
[TBL] [Abstract][Full Text] [Related]
3. Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells.
Liu CY; Su JC; Ni MH; Tseng LM; Chu PY; Wang DS; Tai WT; Kao YP; Hung MH; Shiau CW; Chen KF
Breast Cancer Res Treat; 2014 Jul; 146(1):71-84. PubMed ID: 24903225
[TBL] [Abstract][Full Text] [Related]
4. RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells.
Su JC; Tseng PH; Hsu CY; Tai WT; Huang JW; Ko CH; Lin MW; Liu CY; Chen KF; Shiau CW
Oncotarget; 2014 Jul; 5(13):4909-19. PubMed ID: 24952874
[TBL] [Abstract][Full Text] [Related]
5. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF
Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751
[TBL] [Abstract][Full Text] [Related]
6. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
Wang CY; Chao TT; Tai WT; Chang FY; Su WP; Chen YL; Chen PT; Weng CY; Yuan A; Shiau CW; Yu CJ; Chen KF
J Thorac Oncol; 2014 Apr; 9(4):488-96. PubMed ID: 24736071
[TBL] [Abstract][Full Text] [Related]
7. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
Chao TI; Tai WT; Hung MH; Tsai MH; Chen MH; Chang MJ; Shiau CW; Chen KF
Cancer Lett; 2016 Feb; 371(2):205-13. PubMed ID: 26679051
[TBL] [Abstract][Full Text] [Related]
8. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
Tai WT; Cheng AL; Shiau CW; Liu CY; Ko CH; Lin MW; Chen PJ; Chen KF
Mol Cancer Ther; 2012 Feb; 11(2):452-63. PubMed ID: 22180308
[TBL] [Abstract][Full Text] [Related]
9. A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation.
Chen KF; Su JC; Liu CY; Huang JW; Chen KC; Chen WL; Tai WT; Shiau CW
Cancer Lett; 2012 Aug; 321(1):27-35. PubMed ID: 22465052
[TBL] [Abstract][Full Text] [Related]
10. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma.
Tai WT; Shiau CW; Chen PJ; Chu PY; Huang HP; Liu CY; Huang JW; Chen KF
Hepatology; 2014 Jan; 59(1):190-201. PubMed ID: 23908138
[TBL] [Abstract][Full Text] [Related]
12. Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells.
Yang J; Cai X; Lu W; Hu C; Xu X; Yu Q; Cao P
Cancer Lett; 2013 Jan; 328(2):243-51. PubMed ID: 23032719
[TBL] [Abstract][Full Text] [Related]
13. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.
Tai WT; Shiau CW; Chen HL; Liu CY; Lin CS; Cheng AL; Chen PJ; Chen KF
Cell Death Dis; 2013 Feb; 4(2):e485. PubMed ID: 23392173
[TBL] [Abstract][Full Text] [Related]
14. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
Tai WT; Chu PY; Shiau CW; Chen YL; Li YS; Hung MH; Chen LJ; Chen PL; Su JC; Lin PY; Yu HC; Chen KF
Clin Cancer Res; 2014 Nov; 20(22):5768-76. PubMed ID: 25248379
[TBL] [Abstract][Full Text] [Related]
15. SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model.
Tai WT; Shiau CW; Li YS; Chen YL; Chu PY; Huang JW; Hsu CY; Hsu YC; Chen PJ; Chen KF
Mol Cancer Ther; 2014 Jan; 13(1):27-36. PubMed ID: 24275147
[TBL] [Abstract][Full Text] [Related]
16. Secreted GRP78 activates EGFR-SRC-STAT3 signaling and confers the resistance to sorafeinib in HCC cells.
Li R; Yanjiao G; Wubin H; Yue W; Jianhua H; Huachuan Z; Rongjian S; Zhidong L
Oncotarget; 2017 Mar; 8(12):19354-19364. PubMed ID: 28423613
[TBL] [Abstract][Full Text] [Related]
17. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
Tai WT; Cheng AL; Shiau CW; Huang HP; Huang JW; Chen PJ; Chen KF
J Hepatol; 2011 Nov; 55(5):1041-8. PubMed ID: 21354226
[TBL] [Abstract][Full Text] [Related]
18. Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity.
Tai WT; Shiau CW; Li YS; Chang CW; Huang JW; Hsueh TT; Yu HC; Chen KF
J Hepatol; 2014 Jul; 61(1):89-97. PubMed ID: 24657398
[TBL] [Abstract][Full Text] [Related]
19. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
[TBL] [Abstract][Full Text] [Related]
20. Total alkaloids of Rubus aleaefolius Poir. inhibit the STAT3 signaling pathway leading to suppression of proliferation and cell cycle arrest in a mouse model of hepatocellular carcinoma.
Zhao J; Lin W; Cao Z; Liu L; Zhuang Q; Zhong X; Hong Z; Peng J
Oncol Rep; 2013 Sep; 30(3):1309-14. PubMed ID: 23828071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
